Diagnostics of carcinogenic risk in ulcerative colitis targeting a prostaglandin transporter

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K21288
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor biology; General pharmacology
• Research Institution: Osaka City University
• Principal Investigator: Otani Koji 大阪市立大学, 大学院医学研究科, 講師 (30597555)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 炎症発癌 / プロスタグランジントランスポーター

Outline of Final Research Achievements

Prostaglandin (PG) E2 promotes gastrointestinal carcinogenesis. The total amount of active PGE2 is regulated by the PG biosynthesis and degradation pathways which include cyclooxygenase-2 (COX-2: PG synthase), 15-hydroxyprostaglandin dehydrogenase (15-PGDH: catabolic enzyme of PG), PG transporter (PGT: influx transporter), and multidrug resistance associated protein 4 (MRP4: efflux transporter). We examined the expression of PGT, which transports PG into cell for its metabolic degradation, and the other molecules in colitis-associated carcinogenesis. Increased expression of COX-2 and MRP4 and decreased expression of 15-PGDH and PGT were observed in colon cancer part, and PGE2 contest in colon cancer cell was elevated. PGT expression and PGE2 content were regulated by TNF-α, and it was suggested that there was a function linkage between PGT and 15-PGDH.

Free Research Field

炎症、癌、小腸、内視鏡